<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="125979">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01800474</url>
  </required_header>
  <id_info>
    <org_study_id>05PT1209</org_study_id>
    <nct_id>NCT01800474</nct_id>
  </id_info>
  <brief_title>A Non-interventional Study to Evaluate the Use of Pliaglis in Daily Practice</brief_title>
  <official_title>A Non-interventional Study to Evaluate the Use of Pliaglis in Daily Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multe-center, non-interventional study in Europe to evaluate Pliaglis in dialy practice
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi-center, non-interventional study, including up to 700 subjects at approximately 70
      sites in 5 European countries to evaluate the post-market safety profile of Pliaglis and the
      efficacy of Pliaglis in terms of pain reduction, satisfaction with the product and daily
      practice use prior to pre-defined aesthetic procedures.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Post-market safety profile of Pliaglis assessed on spontaneously reported Adverse Reactions</measure>
    <time_frame>After Pliaglis application and throughout the site visit (day of application)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Pliaglis</measure>
    <time_frame>After completing Pliaglis treatment and procedure, i.e. at the end of the site visit (day of application)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain intensity by VAS, satisfaction with pain reduction, willingness to re-use/recommend Pliaglis</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Health Knowledge, Attitudes, Practice</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient aiming to perform one or more of the following aesthetic procedures:

          1. Pulsed-dye laser therapy

          2. Laser-assisted hair removal

          3. Non-ablative laser resurfacing

          4. Dermal filler injection

          5. Vascular access
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Patient treated with Pliaglis by the Investigator or other healthcare professional
             according to label (refer to SmPC)

          -  Patient had already consented to receive any one or more of the following aesthetic
             procedures after Pliaglis administration:

               1. Pulsed-dye laser therapy

               2. Laser-assisted hair removal

               3. Non-ablative laser resurfacing

               4. Dermal filler injection

               5. Vascular access

        Exclusion Criteria:

          -  Patient treated with other injectable or topical anaesthetic(s) for the pre-defined
             aesthetic procedure

          -  Previous participation in this study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Max Murison, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National coordinating investigator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Swansea Laser Clinic</name>
      <address>
        <city>Swansea</city>
        <zip>SA7 9FH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Max Murison, Dr.</last_name>
      <phone>01267 281905</phone>
      <email>max.murison@btconnect.com</email>
    </contact>
    <investigator>
      <last_name>Max Murison, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 8, 2013</lastchanged_date>
  <firstreceived_date>January 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
